Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365257 · ClinicalTrials.gov registry record · Phase 2
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04365257: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT04365257 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04365257, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
Interventions
- OTHER Standard of care
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04365257
The ClinicalTrials.gov registry entry for NCT04365257 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT04365257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04365257 about?
NCT04365257 is a clinical study titled "Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)". The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04365257?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-05-13. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04365257?
The interventions under investigation include: Standard of care (OTHER), Prazosin (DRUG).
Who is sponsoring clinical trial NCT04365257?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.